Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AssigneeIDEC Pharmaceuticals Corporation
InventorsDarrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Claims14
A method for treatment of B cell lymphoma comprising the step of administering a therapeutically effective amount of immunologically active chimeric anti-CD20 antibody to a human, said antibody being derived from a transfectoma comprising anti-CD20 in TCAE 8, ATCC deposit number 69119.
A method for the treatment of B cell lymphoma comprising the steps of:
- 1) administering, at a first administration period, an immunologically active chimeric anti-CD20 antibody to a human, wherein said chimeric anti-CD20 antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 as deposited with the American Type Culture Collection as ATCC deposit number 69119;
- and,
- 2) administering, at a second administration period, a radiolabeled anti-CD20 antibody to said human.
A method for the treatment of B cell lymphoma comprising the steps of:
- 1) administering to a human having B cell lymphoma, at a first administration period, a first therapeutically effective amount of immunologically active chimeric anti-CD20 antibody produced by a transfectoma comprising anti-CD20 in TCAE8, ATCC deposit number 69119;
- 2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;
- and
- 3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.
Dependencies are inferred from the claim text.